Search This Blog

Monday, March 17, 2025

vTv: FDA Lifted Clinical Hold on Cadisegliatin Program for Diabetes

 Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes

CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months

https://www.globenewswire.com/news-release/2025/03/17/3043683/0/en/vTv-Therapeutics-Announces-FDA-has-Lifted-Clinical-Hold-on-Cadisegliatin-Program-for-Diabetes.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)